Phase 3 trial raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Within hours of his January 2025 inauguration, Trump signed an executive order withdrawing the country from the 2015 Paris Agreement, joining only Iran, Libya and Yemen as the only countries not party to the agreement. The same day, Trump issued Executive Order 14154, "Unleashing American Energy", which included pausing funding for the Inflation Reduction Act, introducing uncertainty as to the energy transition. His administration soon renewed a practice from his first term: removing mentions of climate change across numerous federal government websites that had been reinstated during Joe Biden's intervening term. In February 2025, the administration terminated the Environmental and Climate Justice Block Grant Program. In June 2026, district judge Richard Gergel ruled that the terminations were unlawful and in July 2026 a federal judge ordered the program's remaining $2.8 billion in funds be distributed. In April, Trump dismissed the scientists and experts who compile the National Climate Assessments (NCAs) that are required by Congress, the next assessment having been planned for 2028. The globalchange.gov website—established in 1990 to host legislatively mandated reports such as the NCAs—was taken down altogether at the end of June. In May 2025, NOAA said that its National Centers for Environmental Information would no longer update its Billion-Dollar Weather and Climate Disasters database beyond 2024, and that its information—going as far back as 1980—would be archived.
== Promotion opportunities == A diener can be promoted to positions in the mortuary and forensic areas of practice. Dieners can advance to positions (such as a forensic morgue technician) and perform tasks of greater complexity and mainly works with a forensic pathologist, over a general pathologist. Dieners can be promoted to supervisory positions based upon the gaining of supervisory and administrative skills.
== Further reading == Arthur, Joyce (1996). "Creationism: Bad Science or Immoral Pseudoscience?". Skeptic. 4 (4): 88–93. Archived from the original on March 7, 2012. Montagu, M. F. Ashley, ed. (1984-01-12). Science and Creationism (Kindle ed.). USA: Oxford University Press. ASIN B000QXDJIG. Nelkin, Dorothy (2000) [1986]. The Creation Controversy: Science or Scripture in the Schools. toExcel. ISBN 0-595-00194-7. Numbers, Ronald L. (2006). The Creationists: From Scientific Creationism to Intelligent Design (expanded ed.). Harvard. ISBN 978-0-674-02339-0.
=== Dependence and withdrawal === In one study, symptoms of withdrawal lasted less than three days for most subjects. In an animal study, mitragynine withdrawal symptoms were observed following 14 days of mitragynine intraperitoneal injections in mice and included displays of anxiety, teeth chattering, and piloerection, all of which are characteristic signs of opioid withdrawal in mice and are comparable to morphine withdrawal symptoms in character.
Sources: en.wikipedia.org
== Treatment == Proposed treatments include hyperbaric oxygen, levodopa or carbidopa, aspirin, transvitreal optic neurotomy, bevacizumab and vitrectomy. The Ischemic Optic Neuropathy Decompression Trial observed that while spontaneous visual function deterioration occurred in 12% of 125 control eyes, the condition worsened in 24% of 119 eyes that underwent decompressive surgery. The application of corticosteroids in NAION treatment remains a topic of debate. Research into potential therapies for NAION is ongoing, including studies using animal models to explore neuroprotective treatments for the optic nerve. Despite these efforts, including a clinical trial examining the potential neuroprotective effects of topical brimonidine that was discontinued due to stringent eligibility requirements, effective treatment for idiopathic NAION remains elusive. Further trials have been halted prematurely. A third trial investigated the intravitreal injection of a small interfering ribonucleic acid targeting caspase 2 as a treatment approach.
== External links == The MEROPS online database for peptidases and their inhibitors: A01.004 beta-Secretase: Molecule of the Month Archived 2012-11-21 at the Wayback Machine, by David Goodsell, RCSB Protein Data Bank Human BACE1 genome location and BACE1 gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P56817 (Human Beta-secretase 1) at the PDBe-KB.
In order to measure the time-dependent viscoelastic behavior of polymers dynamic mechanical analysis is often performed. Typically, in these measurements the one side of the hydrogel is subjected to a sinusoidal load in shear mode while the applied stress is measured with a stress transducer and the change in sample length is measured with a strain transducer. One notation used to model the sinusoidal response to the periodic stress or strain is:
The need for an international standard for chemistry was first addressed in 1860 by a committee headed by German scientist Friedrich August Kekulé von Stradonitz. This committee was the first international conference to create an international naming system for organic compounds. The ideas that were formulated at that conference evolved into the official IUPAC nomenclature of organic chemistry. IUPAC is a legacy of this meeting, making it one of the most important historical international collaborations of chemistry societies. IUPAC as such was established in 1919.Since this time, IUPAC has been the official organization with the responsibility of updating and maintaining official organic nomenclature. One notable country excluded from early IUPAC was Germany. Germany's exclusion was a result of prejudice towards it by the Allied powers after World War I. Germany was finally admitted into IUPAC in 1929. However, Nazi Germany was removed from IUPAC during World War II. At this time, IUPAC was affiliated with the Allied powers, but had little involvement with the war effort itself. East and West Germany were only readmitted to IUPAC in 1973. Since World War II, IUPAC has focused on standardizing nomenclature and methods in science. In 2016, IUPAC denounced the use of chlorine as a chemical weapon. In a letter to Ahmet Üzümcü, director of the Organisation for the Prohibition of Chemical Weapons (OPCW), the organization pointed out their concerns in regards to chlorine weapon usage in the Syrian civil war and other places .
=== Pharmacodynamics === Diazoxide acts as a ATP-sensitive potassium channel (KATP) opener. It has been found to act as a positive allosteric modulator of the ionotropic glutamate AMPA and kainate receptors.
Sources: en.wikipedia.org
The case Blizzard Entertainment v. Valve Corporation was settled out of court in May 2012; Valve retained the right to use Dota commercially, while Blizzard reserved the right for fans to use Dota non-commercially. Blizzard changed the names of its own projects to remove the Dota term, and renamed Blizzard All-Stars as Heroes of the Storm. Valve's Dota 2 was released in 2013. In 2014, mobile developers Lilith and uCool released its games Dota Legends and Heroes Charge, respectively. Both were influenced by Dota and the sequels. In 2017, Valve and Blizzard took joint action against these companies, citing copyright issues related to the Dota names. uCool argued that the Dota games were a collective work and could not be copyrighted by anyone in particular, but the presiding judge, Charles R. Breyer, felt that, due to the trio's actions as maintainers of the Dota mods, they had a rightful copyright claim to this. Separately, Lilith and uCool argued that Eul had, in a forum post from September 2004, assigned an open-source copyright license to Dota, which would make Valve and Blizzard's copyright claims void. The case was later heard by a jury.
=== Non-peptide === Adenosine Anamorelin (ONO-7643, RC-1291, ST-1291) Capromorelin (CP-424391) Ibutamoren (MK-677, MK-0677, L-163191, LUM-201) Macimorelin (AEZS-130, JMV 1843) SM-130686 Note that while ulimorelin is a ghrelin receptor agonist, it is not a GHS as it is peripherally selective and has little or no effect on GH secretion. Likewise, adenosine is capable of eliciting a hunger response as a ghrelin agonist but has little to no effect on GH secretion.
Fever is an important metric for the diagnosis of disease in domestic animals. The body temperature of animals, which is taken rectally, is different from one species to another. For example, a horse is said to have a fever above 101 °F (38.3 °C). In species that allow the body to have a wide range of "normal" temperatures, such as camels, whose body temperature varies as the environmental temperature varies, the body temperature which constitutes a febrile state differs depending on the environmental temperature. Fever can also be behaviorally induced by invertebrates that do not have immune-system based fever. For instance, some species of grasshopper will thermoregulate to achieve body temperatures that are 2–5 °C higher than normal to inhibit the growth of fungal pathogens such as Beauveria bassiana and Metarhizium acridum. Honeybee colonies are also able to induce a fever in response to a fungal parasite Ascosphaera apis.
== Bibliography == Capoccia, Anna Rita (2006). "MAGATI, Cesare". Dizionario Biografico degli Italiani (in Italian). Vol. 67: Macchi–Malaspina. Rome: Istituto dell'Enciclopedia Italiana. ISBN 978-88-12-00032-6. Capparoni, Pietro (1932). "Cesare Magati (Padre Liberato da Scandiano dei Minori Cappuccini)". Profili Bio-bibliografici di Medici e Naturalisti Celebri Italiani Dal Secolo XV al Secolo XVIII. Rome: 70–75. Cesare Magati entry (in Italian) by Agostino Palmerini in the Enciclopedia Treccani, 1934 Putti, Vittorio (1941). "Cesare Magati (1579– 1647)". Biografie di Chirurghi Dal XVI a XIX Secolo. Bologna: 9–16. Premuda, Loris (1970). "Magati, Cesare". In Charles Coulston Gillispie (ed.). Dictionary of Scientific Biography. Vol. 9. New York: Charles Scribner's Sons. pp. 4–5.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。